TickerWorth Open the interactive view →

Nanobiotix S.A. (NBTX) — Available-Data Snapshot

Updated Sep 3, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$41.67
Market cap
$2,117,308,672
52-week high
$57.14
52-week low
$8.03
Currency
USD
Exchange
NasdaqGS

We don't publish a discounted-cash-flow fair value for Nanobiotix S.A. (NBTX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, NBTX trades at a recent price of $41.67, a market capitalisation of about $2,117,308,672, sitting 68% of the way up its 52-week range ($8.03–$57.14), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing NBTX's trading multiples against a sector benchmark. Here that gives Fwd P/E of -122.6× (cheaper than the peer median of 16.1×); P/B of -20.5× (cheaper than the peer median of 8.4×); P/S of 65.0× (richer than the peer median of 6.8×); EV/EBITDA of -196.3× (cheaper than the peer median of 17.1×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. NBTX shows a price-to-book (P/B) of -20.54 and book value of $-2.03 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. NBTX is in an up-trend (price above both its 50- and 200-day averages), trading -27.1% from its 52-week high. Over the past year the stock is +360.9%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

What's missing and why: we can't build a DCF for NBTX because the data source doesn't reliably provide dividend. We would rather say so plainly than manufacture a precise-looking number from nothing. As coverage improves, or for larger and more widely-followed listings, a full intrinsic-value model becomes possible.

Relative valuation — NBTX vs peers

MultipleNBTXPeer median
Fwd P/E-122.6×16.1×cheaper than
P/B-20.5×8.4×cheaper than
P/S65.0×6.8×richer than
EV/EBITDA-196.3×17.1×cheaper than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
-20.54
Book value / share
$-2.03

Below book (P/B < 1) can flag either a discount to net assets or the market pricing in trouble — it is descriptive, not a buy signal.

Price-based snapshot

50-day avg
$39.37
200-day avg
$31.92
From 52-wk high
-27.1%
1-year momentum
+360.9%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive NBTX view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.